Abstract: The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy.

Abstract: The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy.

Abstract: Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the restless-legs-syndrome.

Abstract: Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the restless-legs-syndrome.

Abstract: Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy.

Abstract: Medicinal agents are claimed exhibiting sustained release of active compound, containing a solid active ingredient, poorly soluble in water, and auxiliary agents, characterized in that the active compound, in a microcrystalline form or in form of a molecular dispersion, is distributed in or on pellets, and that the pellets are covered by a membrane having retarded permeability with respect to the active compound.

Abstract: The invention relates to nifedipine combination preparations, containing nifedipine with delayed release of active agent and a .beta.-blocker in each case in granulated form, and their pharmaceutical usage as a therapeutic agent in cardiovascular diseases.